-
Reduction in hemoglobin-oxygen affinity results in the improvement of exercise capacity in mice with chronic heart failure.
Journal of the American College of Cardiology 20080826
-
Trimethylaluminium mediated amide bond formation in a continuous flow microreactor as key to the synthesis of rimonabant and efaproxiral.
Chemical communications (Cambridge, England) 20080307
-
Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases.
American journal of clinical oncology 20071201
-
The effects of Efaproxyn (efaproxiral) on subcutaneous RIF-1 tumor oxygenation and enhancement of radiotherapy-mediated inhibition of tumor growth in mice.
Radiation research 20070801
-
Using exposure-response and biomarkers to streamline early drug development.
Ernst Schering Research Foundation workshop 20070101
-
Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastases.
British journal of cancer 20060619
-
Role of efaproxiral in metastatic brain tumors.
Expert review of anticancer therapy 20060401
-
Whole-brain radiotherapy with or without efaproxiral for the treatment of brain metastases: Determinants of response and its prognostic value for subsequent survival.
International journal of radiation oncology, biology, physics 20060315
-
Mass spectrometric characterization of efaproxiral (RSR13) and its implementation into doping controls using liquid chromatography-atmospheric pressure ionization-tandem mass spectrometry.
Journal of mass spectrometry : JMS 20060301
-
Efaproxiral (RSR13) plus oxygen breathing increases the therapeutic ratio of carboplatin in EMT6 mouse mammary tumors.
Experimental biology and medicine (Maywood, N.J.) 20060301
-
Radiation sensitization with redox modulators: a promising approach.
International journal of radiation oncology, biology, physics 20060201
-
New hope for old drug in patients with brain metastases.
The Lancet. Oncology 20060201
-
Efaproxiral: should we hold our breath?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060101
-
Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060101
-
Efaproxiral: a radiation enhancer used in brain metastases from breast cancer.
The Annals of pharmacotherapy 20051201
-
Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050901
-
Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study.
International journal of radiation oncology, biology, physics 20050401
-
Hit to Lead Success Stories--IBC Conference: Effective chemistry strategies for reducing attrition rates and speeding lead compounds into the pipeline. 31 January-1 February 2005, San Diego, CA, USA.
IDrugs : the investigational drugs journal 20050301
-
R-state hemoglobin bound to heterotropic effectors: models of the DPG, IHP and RSR13 binding sites.
FEBS letters 20050131
-
Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
Drugs in R&D 20050101
-
Effects of a pharmacologically-induced shift of hemoglobin-oxygen dissociation on myocardial energetics during ischemia in patients with coronary artery disease.
Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20050101
-
Modeling of the response of ptO2 in rat brain to changes in physiological parameters.
Advances in experimental medicine and biology 20050101
-
Effect of RSR13, an allosteric hemoglobin modifier, on oxygenation in murine tumors: an in vivo electron paramagnetic resonance oximetry and bold MRI study.
International journal of radiation oncology, biology, physics 20040701
-
Efaproxiral: a novel radiation sensitiser.
Expert opinion on investigational drugs 20040501
-
Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
Cancer chemotherapy and pharmacology 20040101
-
Efaproxiral (Allos Therapeutics).
IDrugs : the investigational drugs journal 20030801
-
RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030615
-
Allosteric modification of hemoglobin by RSR13 as a therapeutic strategy.
Advances in experimental medicine and biology 20030101
-
The dose-dependent effect of RSR13, a synthetic allosteric modifier of hemoglobin, on physiological parameters and brain tissue oxygenation in rats.
Advances in experimental medicine and biology 20030101
-
The effect of RSR13, a synthetic allosteric modifier of hemoglobin, on brain tissue pO2 (measured by EPR oximetry) following severe hemorrhagic shock in rats.
Advances in experimental medicine and biology 20030101
-
[Blood doping and cardiovascular consequences].
Presse medicale (Paris, France : 1983) 20021221
-
Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020715
-
Increasing P(50) does not improve DO(2CRIT) or systemic VO(2) in severe anemia.
American journal of physiology. Heart and circulatory physiology 20020701
-
Pharmacological correction of hypothermic P(50) shift does not alter outcome from focal cerebral ischemia in rats.
American journal of physiology. Heart and circulatory physiology 20020501
-
Effects of enhanced oxygen release from hemoglobin by RSR13 in an acute renal failure model.
Kidney international 20011001
-
Enhancement of tumor oxygenation and radiation response by the allosteric effector of hemoglobin, RSR13.
Radiation research 20010901
-
High-resolution crystal structure of deoxy hemoglobin complexed with a potent allosteric effector.
Protein science : a publication of the Protein Society 20010501
-
A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics.
International journal of radiation oncology, biology, physics 20010315
-
Allosteric modification of oxygen delivery by hemoglobin.
Anesthesia and analgesia 20010301
-
RSR13, a potential athletic performance enhancement agent: detection in urine by gas chromatography/mass spectrometry.
Rapid communications in mass spectrometry : RCM 20010101
